Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sirisha, Mushti"'
Autor:
Yuan-Li Shen, Sirisha Mushti, Flora Mulkey, Thomas Gwise, Xin Wang, Jiaxi Zhou, Xin Gao, Shenghui Tang, Marc R. Theoret, Richard Pazdur, Rajeshwari Sridhara
Publikováno v:
Statistics in Biopharmaceutical Research. 15:315-317
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::452b56c7408c76e39ecb4b8c44f0af93
https://doi.org/10.1080/19466315.2023.2203007
https://doi.org/10.1080/19466315.2023.2203007
Autor:
Sirisha Mushti, Lola Fashoyin-Aje, Steven Lemery, Marc R. Theoret, Kirsten B. Goldberg, Joyce Cheng, Lorraine Pelosof, May Tun Saung, Xiling Jiang, Richard Pazdur, Martha Donoghue, Jiang Liu, Sandra Casak, Maryam Khazraee, Hong Zhao
Publikováno v:
Oncologist
On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab (OPDIVO; Bristol Myers Squibb, New York, NY) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::766473e2ccf3c3137bcb8ffa612dedbc
https://doi.org/10.1002/onco.13646
https://doi.org/10.1002/onco.13646
Autor:
Julia A. Beaver, Whitney S. Helms, Harpreet Singh, Jiang Liu, Reena Philip, Diana Bradford, Dun Liang, Francisca Reyes Turcu, Amy M. Skinner, Rosane Charlab, Shenghui Tang, Soma Ghosh, Lauren S. L. Price, Marc R. Theoret, Richard Pazdur, Erin Larkins, Donna Roscoe, Yangbing Li, Jeanne Fourie Zirkelbach, Sirisha Mushti, Autumn Zack-Taylor, Lisa Rodriguez, Paul G. Kluetz
Publikováno v:
Clinical Cancer Research. 27:2130-2135
On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::842813bad208e8eb140a01e30788d85c
https://doi.org/10.1158/1078-0432.ccr-20-3558
https://doi.org/10.1158/1078-0432.ccr-20-3558
Autor:
Shen, Yuan-Li, Wang, Xin, Sirisha, Mushti, Mulkey, Flora, Zhou, Jiaxi, Gao, Xin, Zhang, Lijun, Gwise, Thomas, Tang, Shenghui, Theoret, Marc, Pazdur, Richard, Sridhara, Rajeshwari
Publikováno v:
Statistics in Biopharmaceutical Research; Apr-Jun2023, Vol. 15 Issue 2, p300-309, 10p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kirsten B. Goldberg, Lola Fashoyin-Aje, William F. Pierce, Marc R. Theoret, Sirisha Mushti, Paul G. Kluetz, Richard Pazdur, Yuan Li Shen, Leah Her, Leigh Marcus, Sandra Casak, Steven Lemery, Joyce Cheng
Publikováno v:
Clin Cancer Res
The FDA approved pembrolizumab on June 29, 2020, for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer with no prior systemic treatment for advanced disease. The approval was based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363be90aa542b7139583b6586788a137
https://pubmed.ncbi.nlm.nih.gov/33846198
https://pubmed.ncbi.nlm.nih.gov/33846198
Autor:
Kirsten B. Goldberg, Harpreet Singh, Sirisha Mushti, Flora Mulkey, Steven Lemery, Julia A. Beaver, Shenghui Tang, Rajeshwari Sridhara, Richard Pazdur, Marc R. Theoret, Patricia Keegan, Paul G. Kluetz
Publikováno v:
Current Oncology Reports. 22
This review provides a comprehensive assessment of recent literature reports describing atypical response patterns observed with immune checkpoint inhibitors (ICIs), modifications to response evaluation criteria for ICIs, and treatment beyond progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a4b266ef48b385b29759c1de8307730
https://doi.org/10.1007/s11912-020-00974-z
https://doi.org/10.1007/s11912-020-00974-z
Publikováno v:
Clinical Cancer Research. 24:2268-2275
Purpose: With the approval of immunotherapies for a variety of indications, methods to assess treatment benefit addressing the response patterns observed are important. We evaluated RECIST criteria–based overall response rate (ORR) and progression-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::042c07f92bb45e34718459d64a134618
https://doi.org/10.1158/1078-0432.ccr-17-1902
https://doi.org/10.1158/1078-0432.ccr-17-1902
Autor:
Xianhua Cao, Marc R. Theoret, Meredith Libeg, Liang Zhao, Whitney S. Helms, Kun He, Laurie Graham, Richard Pazdur, Meredith K. Chuk, Hongshan Li, Joel T. Welch, Hong Zhao, Maitreyee Hazarika, Rajeshwari Sridhara, Alexander H. Putman, Sirisha Mushti, Shawna L. Weis, Patricia Keegan
Publikováno v:
Clinical Cancer Research. 23:3484-3488
On December 22, 2014, the FDA granted accelerated approval to nivolumab (OPDIVO; Bristol-Myers Squibb) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7bc35b67a158b74e0bb24405e795d5
https://doi.org/10.1158/1078-0432.ccr-16-0712
https://doi.org/10.1158/1078-0432.ccr-16-0712
Autor:
Meredith Libeg, Kirsten B. Goldberg, Richard Pazdur, Rajeshwari Sridhara, Julia A. Beaver, Amy E. McKee, Marc R. Theoret, Sirisha Mushti, Kun He, Patricia Keegan
Publikováno v:
Clinical Cancer Research. 23:3479-3483
On November 23, 2015, the FDA approved nivolumab (OPDIVO; Bristol-Myers Squibb) as a single agent for the first-line treatment of patients with BRAFV600 wild-type, unresectable or metastatic melanoma. An international, double-blind, randomized (1:1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62c8cf4c71c45fc05734b7670dcc4cbb
https://doi.org/10.1158/1078-0432.ccr-16-0714
https://doi.org/10.1158/1078-0432.ccr-16-0714